Skip Nav Destination
Issues
15 February 2022
-
Cover Image
Cover Image
The cover shows a section of a biopsy from a patient with diffuse large B-cell lymphoma. Multiplex immunohistochemistry staining shows infiltration of T cells and NK cells as well as TIM3 expression in the lymphoma microenvironment. The image depicts CD45 in magenta, CD3 in blue, CD56 in yellow, TIM3 in red, Granzyme B in green, and DAPI in gray. For details, see the article by Autio and colleagues on page 781 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Reviews
Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma
Kirit Singh; Kristen A. Batich; Patrick Y. Wen; Aaron C. Tan; Stephen J. Bagley; Michael Lim; Michael Platten; Howard Colman; David M. Ashley; Susan M. Chang; Rifaquat Rahman; Evanthia Galanis; Alireza Mansouri; Vinay K. Puduvalli; David A. Reardon; Solmaz Sahebjam; John H. Sampson; John Simes; Donald A. Berry; Gelareh Zadeh; Tim F. Cloughesy; Minesh P. Mehta; Steven Piantadosi; Michael Weller; Amy B. Heimberger; Mustafa Khasraw
Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement
Stephen J. Bagley; Shawn Kothari; Rifaquat Rahman; Eudocia Q. Lee; Gavin P. Dunn; Evanthia Galanis; Susan M. Chang; Louis Burt Nabors; Manmeet S. Ahluwalia; Roger Stupp; Minesh P. Mehta; David A. Reardon; Stuart A. Grossman; Erik P. Sulman; John H. Sampson; Simon Khagi; Michael Weller; Timothy F. Cloughesy; Patrick Y. Wen; Mustafa Khasraw
Perspectives
Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Anthony R. Mato; Matthew S. Davids; Jeff Sharman; Lindsey E. Roeker; Neil Kay; Arnon P. Kater; Kerry Rogers; Meghan C. Thompson; Joanna Rhodes; Andre Goy; Alan Skarbnik; Stephen J. Schuster; Constantine S. Tam; Toby A. Eyre; Susan O'Brien; Chadi Nabhan; Nicole Lamanna; Clare Sun; Mazyar Shadman; John M. Pagel; Chaitra Ujjani; Danielle Brander; Catherine C. Coombs; Nitin Jain; Chan Y. Cheah; Jennifer R. Brown; John F. Seymour; Jennifer A. Woyach
Special Report
Research Briefs: Clinical Trial Brief Reports
A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222
Halle C.F. Moore; William E. Barlow; George Somlo; Julie R. Gralow; Anne F. Schott; Daniel F. Hayes; Peter Kuhn; James B. Hicks; Lisa Welter; Philip A. Dy; Christina H. Yeon; Alison K. Conlin; Ernie Balcueva; Danika L. Lew; Debasish Tripathy; Lajos Pusztai; Gabriel N. Hortobagyi
Clinical Trials: Targeted Therapy
First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study
Jian Zhang; Dongmei Ji; Li Cai; Herui Yao; Min Yan; Xiaojia Wang; Weina Shen; Yiqun Du; Hui Pang; Xiuping Lai; Huiai Zeng; Jian Huang; Yan Sun; Xinxin Peng; Junfang Xu; Jing Yang; Fei Yang; Ting Xu; Xichun Hu
Trilaciclib Prior to Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer: Final Efficacy and Subgroup Analysis from a Randomized Phase II Study
Antoinette R. Tan; Gail S. Wright; Anu R. Thummala; Michael A. Danso; Lazar Popovic; Timothy J. Pluard; Hyo S. Han; Željko Vojnović; Nikola Vasev; Ling Ma; Donald A. Richards; Sharon T. Wilks; Dušan Milenković; Jie Xiao; Jessica Sorrentino; Janet Horton; Joyce O'Shaughnessy
Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
Xin Hua; Xi-Wen Bi; Jian-Li Zhao; Yan-Xia Shi; Ying Lin; Zhi-Yong Wu; Yuan-Qi Zhang; Le-Hong Zhang; An-Qing Zhang; Heng Huang; Xin-Mei Liu; Fei Xu; Ying Guo; Wen Xia; Ruo-Xi Hong; Kui-Kui Jiang; Cong Xue; Xin An; Yong-Yi Zhong; Shu-Sen Wang; Jia-Jia Huang; Zhong-Yu Yuan; for the South China Breast Cancer Group (SCBCG)
Adding Base-Excision Repair Inhibitor TRC102 to Standard Pemetrexed–Platinum–Radiation in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer: Results of a Phase I Trial
Tithi Biswas; Afshin Dowlati; Charles A. Kunos; John J. Pink; Nancy L. Oleinick; Shakun Malik; Pingfu Fu; Shufen Cao; Debora S. Bruno; David L. Bajor; Monaliben Patel; Stanton L. Gerson; Mitchell Machtay
Pamiparib Monotherapy for Patients with Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated with at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study
Xiaohua Wu; Jianqing Zhu; Jing Wang; Zhongqiu Lin; Rutie Yin; Wei Sun; Qi Zhou; Songling Zhang; Danbo Wang; Hong Shi; Yunong Gao; Yi Huang; Guiling Li; Xiuli Wang; Ying Cheng; Ge Lou; Qinglei Gao; Li Wang; Xiuping Du; Mei Pan; Xiyan Mu; Li Li; Miao Li; Song Mu; Beihua Kong
Clinical Trials: Immunotherapy
Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma
Daniel P. Regan; Lyndah Chow; Sunetra Das; Laurel Haines; Eric Palmer; Jade N. Kurihara; Jonathan W. Coy; Alissa Mathias; Douglas H. Thamm; Daniel L. Gustafson; Steven W. Dow
Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas
Funda Meric-Bernstam; Randy F. Sweis; F. Stephen Hodi; Wells A. Messersmith; Robert H.I. Andtbacka; Matthew Ingham; Nancy Lewis; Xinhui Chen; Marc Pelletier; Xueying Chen; Jincheng Wu; Thomas W. Dubensky; Sarah M. McWhirter; Thomas Müller; Nitya Nair; Jason J. Luke
A Phase I Study of Autologous Dendritic Cell Vaccine Pulsed with Allogeneic Stem-like Cell Line Lysate in Patients with Newly Diagnosed or Recurrent Glioblastoma
Jethro L. Hu; Oluwaseun A. Omofoye; Jeremy D. Rudnick; Sungjin Kim; Mourad Tighiouart; Surasak Phuphanich; Hongqiang Wang; Mia Mazer; Toni Ganaway; Ray M. Chu; Chirag G. Patil; Keith L. Black; Stephen L. Shiao; Rongfu Wang; John S. Yu
Precision Medicine and Imaging
Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response
Qing Zhou; Simon P. Gampenrieder; Sophie Frantal; Gabriel Rinnerthaler; Christian F. Singer; Daniel Egle; Georg Pfeiler; Rupert Bartsch; Viktor Wette; Angelika Pichler; Edgar Petru; Peter C. Dubsky; Zsuzsanna Bago-Horvath; Christian Fesl; Margaretha Rudas; Anders Ståhlberg; Ricarda Graf; Sabrina Weber; Nadia Dandachi; Martin Filipits; Michael Gnant; Marija Balic; Ellen Heitzer; on behalf of the ABCSG
Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer
Joseph E. Grossman; Lakshmi Muthuswamy; Ling Huang; Dipikaa Akshinthala; Sofia Perea; Raul S. Gonzalez; Leo L. Tsai; Jonah Cohen; Bruno Bockorny; Andrea J. Bullock; Benjamin Schlechter; Mary Linton B. Peters; Catherine Conahan; Supraja Narasimhan; Christine Lim; Roger B. Davis; Robert Besaw; Mandeep S. Sawhney; Douglas Pleskow; Tyler M. Berzin; Martin Smith; Tara S. Kent; Mark Callery; Senthil K. Muthuswamy; Manuel Hidalgo
Cell-Free HPV DNA Provides an Accurate and Rapid Diagnosis of HPV-Associated Head and Neck Cancer
Giulia Siravegna; Connor J. O'Boyle; Shohreh Varmeh; Natalia Queenan; Alexa Michel; Jarrod Stein; Julia Thierauf; Peter M. Sadow; William C. Faquin; Simon K. Perry; Adam Z. Bard; Wei Wang; Daniel G. Deschler; Kevin S. Emerick; Mark A. Varvares; Jong C. Park; John R. Clark; Annie W. Chan; Vanessa Carlota Andreu Arasa; Osamu Sakai; Jochen Lennerz; Ryan B. Corcoran; Lori J. Wirth; Derrick T. Lin; A. John Iafrate; Jeremy D. Richmon; Daniel L. Faden
Translational Cancer Mechanisms and Therapy
Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
Mehmet A. Bilen; Brian I. Rini; Martin H. Voss; James Larkin; John B.A.G. Haanen; Laurence Albiges; Lance C. Pagliaro; Eric G. Voog; Elaine T. Lam; Nikolay Kislov; Bradley A. McGregor; Aly-Khan A. Lalani; Bo Huang; Alessandra di Pietro; Stan Krulewicz; Paul B. Robbins; Toni K. Choueiri
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial
Thomas Denize; Subrina Farah; Alessia Cimadamore; Abdallah Flaifel; Emily Walton; Maura A. Sticco-Ivins; Chris Labaki; David A. Braun; Maxine Sun; Evelyn Wang; Wanling Xie; Toni K. Choueiri; Sabina Signoretti
DNMT3A Harboring Leukemia-Associated Mutations Directs Sensitivity to DNA Damage at Replication Forks
Kartika Venugopal; Yang Feng; Pawel Nowialis; Huanzhou Xu; Daniil E. Shabashvili; Cassandra M. Berntsen; Prabhjot Kaur; Kathryn I. Krajcik; Christina Taragjini; Zachary Zaroogian; Heidi L. Casellas Román; Luisa M. Posada; Chamara Gunaratne; Jianping Li; Daphné Dupéré-Richer; Richard L. Bennett; Santhi Pondugula; Alberto Riva; Christopher R. Cogle; Rene Opavsky; Brian K. Law; Sumita Bhaduri-McIntosh; Stefan Kubicek; Philipp B. Staber; Jonathan D. Licht; Jonathan E. Bird; Olga A. Guryanova
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Jürgen Wichmann; Caroline Rynn; Thomas Friess; Jeannine Petrig-Schaffland; Martin Kornacker; Cornelia Handl; Jasmin Emmenegger; Jan Eckmann; Frank Herting; Nicolas Frances; Daniel Hunziker; Daniela Krummenacher; Dominik Rüttinger; Alison Ribeiro; Marina Bacac; Alessandro Brigo; David S. Hewings; Reinhard Dummer; Mitchell P. Levesque; Gabriel Schnetzler; Bruno Martoglio; James R. Bischoff; Piergiorgio Pettazzoni
Anlotinib Induces a T Cell–Inflamed Tumor Microenvironment by Facilitating Vessel Normalization and Enhances the Efficacy of PD-1 Checkpoint Blockade in Neuroblastoma
Yudong Su; Bingying Luo; Yao Lu; Daowei Wang; Jie Yan; Jian Zheng; Jun Xiao; Yangyang Wang; Zhenyi Xue; Jie Yin; Peng Chen; Long Li; Qiang Zhao
Advertisement
